Health Care Costs Following COVID-19 Hospitalization Prior to Vaccine Availability

References

1. 1.↵
   CDC. What is long COVID? Available at: https://www.covid.gov/longcovid/definitions. Published 2022. Accessed 2/7/2023, 2023.
2. 2.↵
   1. Yomogida K,
   2. Zhu S,
   3. Rubino F,
   4. Figueroa W,
   5. Balanji N,
   6. Holman E

   . Post-acute sequelae of SARS-CoV-2 infection among adults aged ≥ 18 years—Long Beach, California, April 1–December 10, 2020. MMWR Morb Mortal Wkly Rep 2021;70:1274–7.

   OpenUrl
3. 3.↵
   1. Cabrera Martimbianco AL,
   2. Pacheco RL,
   3. Bagattini ÂM,
   4. Riera R

   . Frequency, signs and symptoms, and criteria adopted for long COVID‐19: A systematic review. Int J Clin Pract 2021;75:e14357.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Huang C,
   2. Huang L,
   3. Wang Y,
   4. et al

   . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Santa Cruz A,
   2. Mendes-Frias A,
   3. Azarias-da-Silva M,
   4. et al

   . Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8+ β7 integrin+ T cells and anti-SARS-CoV-2 IgA response. Nat Commun 2023;14:1772.

   OpenUrl
6. 6.↵
   1. Evans RA,
   2. Leavy OC,
   3. Richardson M,
   4. et al

   . Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. The Lancet Respiratory Medicine 2022;10:761–75.

   OpenUrl
7. 7.↵
   1. Bell ML,
   2. Catalfamo CJ,
   3. Farland LV,
   4. et al

   . Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. PLoS One 2021;16:e0254347.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Garrigues E,
   2. Janvier P,
   3. Kherabi Y,
   4. et al

   . Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020;81:e4–e6.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Alkodaymi MS,
   2. Omrani OA,
   3. Fawzy NA,
   4. et al

   . Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clinical Microbiology and Infection 2022;28:657–66.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Mainous AG,
    2. Rooks BJ,
    3. Orlando FA

    . Risk of new hospitalization post-COVID-19 infection for non-COVID-19 conditions. J Am Board Fam Med 2021;34:907–13.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Mainous AG III.,
    2. Rooks BJ,
    3. Wu V,
    4. Orlando FA

    . COVID-19 post-acute sequelae among adults: 12 month mortality risk. Front Med (Lausanne) 2021;8:778434.

    OpenUrl
12. 12.↵
    1. Mainous A,
    2. Rooks B,
    3. Orlando F

    . The impact of initial COVID-19 episode inflammation among adults on mortality within 12 months post hospital discharge. Annals Family Med; 2023;21 (Supplement 1):3496.
13. 13.↵
    1. Al-Aly Z,
    2. Xie Y,
    3. Bowe B

    . High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021;594:259–64.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Ayoubkhani D,
    2. Khunti K,
    3. Nafilyan V,
    4. et al

    . Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. bmj 2021;372:n693.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Logue JK,
    2. Franko NM,
    3. McCulloch DJ,
    4. et al

    . Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2021;4:e210830-e210830.

    OpenUrl
16. 16.↵
    1. Mainous AG III.,
    2. Rooks BJ,
    3. Orlando FA

    . The impact of initial COVID-19 episode inflammation among adults on mortality within 12 months post-hospital discharge. Front Med (Lausanne) 2022;9:891375.

    OpenUrl
17. 17.↵
    1. Koumpias AM,
    2. Schwartzman D,
    3. Fleming O

    . Long-haul COVID: healthcare utilization and medical expenditures 6 months post-diagnosis. BMC Health Serv Res 2022;22:1010.

    OpenUrlPubMed
18. 18.↵
    1. Cutler DM

    . The costs of long COVID. JAMA Health Forum 2022;3:e221809.

    OpenUrl
19. 19.↵
    1. Jason L,
    2. Mirin A

    . Updating the National Academy of Medicine ME/CFS prevalence and economic impact figures to account for population growth and inflation. Fatigue: Biomedicine, Health & Behavior 2021;9:9–13.

    OpenUrl
20. 20.↵
    1. Havers FP,
    2. Pham H,
    3. Taylor CA,
    4. et al

    . COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥ 18 years–COVID-NET, 13 states. MedRxiv. January 1–July 24, 2021;2021:2008–27.21262356.
21. 21.↵
    1. Tian F,
    2. Chen Z,
    3. Feng Q

    . Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis. J Med Virol 2023;95:e28732.

    OpenUrl
22. 22.↵
    1. Wiemken TL,
    2. McGrath LJ,
    3. Andersen KM,
    4. et al

    . Coronavirus disease 2019 severity and risk of subsequent cardiovascular events. Clinical Infectious Diseases 2023;76:e42–e50.

    OpenUrl
23. 23.↵
    1. Ahmad FB,
    2. Cisewski JA,
    3. Miniño A,
    4. Anderson RN

    . Provisional mortality data—United States, 2020. MMWR Morb Mortal Wkly Rep 2021;70:519–22.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Kompaniyets L,
    2. Pennington AF,
    3. Goodman AB,
    4. et al

    . Peer reviewed: underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19. Prev Chronic Dis March 2020–March 2021;18:E66.
25. 25.↵
    1. Ohsfeldt RL,
    2. Choong CK-C,
    3. Mc Collam PL,
    4. Abedtash H,
    5. Kelton KA,
    6. Burge R

    . Inpatient hospital costs for COVID-19 patients in the United States. Adv Ther 2021;38:5557–95.

    OpenUrlCrossRef